AU727391B2 - Methods of treating or preventing cardiac arrhythmia - Google Patents

Methods of treating or preventing cardiac arrhythmia Download PDF

Info

Publication number
AU727391B2
AU727391B2 AU51549/98A AU5154998A AU727391B2 AU 727391 B2 AU727391 B2 AU 727391B2 AU 51549/98 A AU51549/98 A AU 51549/98A AU 5154998 A AU5154998 A AU 5154998A AU 727391 B2 AU727391 B2 AU 727391B2
Authority
AU
Australia
Prior art keywords
substituted
substituents
aryl
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51549/98A
Other languages
English (en)
Other versions
AU5154998A (en
Inventor
Bernard Fermini
Joseph J. Lynch Jr.
Joseph J Salata
Richard J. Swanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5154998A publication Critical patent/AU5154998A/en
Application granted granted Critical
Publication of AU727391B2 publication Critical patent/AU727391B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51549/98A 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia Ceased AU727391B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2934996P 1996-10-31 1996-10-31
US60/029349 1996-10-31
PCT/US1997/019648 WO1998018476A1 (en) 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia

Publications (2)

Publication Number Publication Date
AU5154998A AU5154998A (en) 1998-05-22
AU727391B2 true AU727391B2 (en) 2000-12-14

Family

ID=21848595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51549/98A Ceased AU727391B2 (en) 1996-10-31 1997-10-29 Methods of treating or preventing cardiac arrhythmia

Country Status (8)

Country Link
US (3) US5935945A (https=)
EP (1) EP0946183B1 (https=)
JP (1) JP2001503413A (https=)
AT (1) ATE361078T1 (https=)
AU (1) AU727391B2 (https=)
CA (1) CA2268922C (https=)
DE (1) DE69737689T2 (https=)
WO (1) WO1998018476A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
DK1087934T3 (da) 1998-04-01 2004-06-28 Cardiome Pharma Corp Aminocyclohexyletherforbindelser og anvendelser deraf
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002098287A2 (en) * 2001-06-06 2002-12-12 The Trustees Of Columbia University In The City Of New York A high throughput biological heart rate monitor that is molecularly determined
US6783979B2 (en) 2001-06-06 2004-08-31 The Trustees Of Columbia University In The City Of New York Research Foundation Of State University Of New York Vectors encoding HCN channels and MiRP1
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
CA2524323C (en) * 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005082424A1 (en) * 2004-02-26 2005-09-09 Merck & Co., Inc. Biological assay
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US8263638B2 (en) * 2004-11-08 2012-09-11 Cardiome Pharma Corp. Dosing regimens for ion channel modulating compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (https=) 2011-07-01 2018-04-28
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP3206702A1 (en) * 2014-10-16 2017-08-23 Academisch Medisch Centrum Nk3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
HU214320B (hu) * 1991-12-20 1998-03-02 EGIS Gyógyszergyár Rt. Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia

Also Published As

Publication number Publication date
ATE361078T1 (de) 2007-05-15
AU5154998A (en) 1998-05-22
US6214809B1 (en) 2001-04-10
EP0946183B1 (en) 2007-05-02
WO1998018476A1 (en) 1998-05-07
CA2268922C (en) 2004-12-28
JP2001503413A (ja) 2001-03-13
US5935945A (en) 1999-08-10
EP0946183A4 (en) 2001-07-18
CA2268922A1 (en) 1998-05-07
DE69737689D1 (de) 2007-06-14
US6214810B1 (en) 2001-04-10
DE69737689T2 (de) 2008-01-31
EP0946183A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
AU727391B2 (en) Methods of treating or preventing cardiac arrhythmia
AU723693B2 (en) Methods of treating or preventing cardiac arrhythmia
CA2481192C (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
JP4352613B2 (ja) 血管新生促進剤及び血管新生作用増強剤
Robertson et al. Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1, 3-dihydro-3, 3-dimethyl-5-(1, 4, 5, 6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one
JPWO1991016314A1 (ja) ピリダジノン誘導体
US4866196A (en) Phenoxyacetic acid derivatives and preparation thereof
GB2277446A (en) Quinazolinones useful as endothelin antagonists
KR100232324B1 (ko) 허혈성 질환을 예방 및 치료하기 위한 트로폴론 유도체 및 그의 약학 조성물
CZ43599A3 (cs) Použití derivátů hydroxylaminu k přípravě léčiva pro léčbu a prevenci nemocí spojených s dysfunkci vaskulárních endoteliálních buněk a farmaceutický přípravek tyto látky obsahující
AU609406B2 (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
EP1341539B1 (en) Anti-inflammatory agents
CA2124340A1 (en) Lithium salt of 2-0-alkylascorbic acid
RU2195273C2 (ru) Фармацевтические продукты для лечения и профилактики заболеваний, появляющихся в результате повреждения эндотелиальных клеток сосудов
IE44886B1 (en) Quinoline carboxylic acid esters
KR20010081067A (ko) 발기기능장애 치료제
Fleckenstein-Grün Gallopamil: Cardiovascular scope of action of a highly specific calcium antagonist
Undrovinas et al. Research Article Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current
JPH07252237A (ja) ピリダジノン誘導体
JPH0778048B2 (ja) タウリン型化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)